BRANDON KOPKIN: Open Payments
NPI 1710467238 · TAMPA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,536 in 77 payments from 19 companies in 2025. Trend: 2023 $1,771 · 2024 $1,138 · 2025 $1,536
Food & beverage: $1,536
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 11 | $242 |
| Otsuka America Pharmaceutical, Inc. | 11 | $171 |
| Vanda Pharmaceuticals Inc. | 6 | $165 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $121 |
| Alkermes, Inc. | 4 | $96 |
| ABBVIE INC. | 4 | $86 |
| Axsome Therapeutics, Inc. | 3 | $83 |
| Teva Pharmaceuticals USA, Inc. | 5 | $81 |
| Corium, LLC | 7 | $81 |
| Lundbeck LLC | 4 | $79 |
Products named: REXULTI, INGREZZA, CAPLYTA, HETLIOZ, VRAYLAR, Auvelity, AUSTEDO XR, Azstarys.
Industry payments across FL — which companies pay providers there.
